FEB 27, 2019 1:30 PM PST

Comprehensive NTRK Fusion Detection, Agnostic of the Fusion Partner, for Optimal Identification of Rare Genomic Events Using TruSightTM Oncology 500

Presented at: Drug Discovery 2019
Sponsored by: Illumina
C.E. Credits: P.A.C.E. CE Florida CE
Speakers
  • Chief Medical Officer, Illumina, Inc.
    Biography
      For the past 25 years, Dr. Febbo has worked at leading institutions throughout the United States, most recently serving as CMO of Genomic Health (NASDAQ:GHDX). Prior to joining Genomic Health, Dr. Febbo served as Professor of Medicine and Urology at the University of California, San Francisco (UCSF), where his laboratory focused on using genomics to understand the biology and clinical behavior of prostate cancer, and his clinical practice focused on genitourinary oncology. While at UCSF, Dr. Febbo was the co-leader of the Prostate Cancer Program at the Helen Diller Family Comprehensive Cancer Center and the Program Principal Investigator of the Translational Research Program for the Alliance for Clinical Trials in Oncology.

      Dr. Febbo holds a Bachelor of Arts degree in Biology from Dartmouth College, received his M.D. degree at UCSF, and completed his internal medicine residency at the Brigham and Women's Hospital. After his fellowship in medical oncology at the Dana-Farber Cancer Institute, he was an Attending Physician in the Genitourinary Oncology Center at Dana-Farber, Instructor at Harvard Medical School, and a post-doctoral fellow in Dr. Todd Golub's laboratory at Dana-Farber, as well as the Whitehead Institute Center for Genomic Research of MIT (now the Broad Institute). In 2004, Dr. Febbo moved to Duke University Medical Center's Institute of Genome Sciences and Policy. He has been a member of the American Society for Clinical Investigation since 2009.
    • Clinical Oncology Marketing, Illumina, Inc.
      Biography
        Maude is a specialist in molecular biology applications in oncology, across technologies and platforms. Her experience includes contributing to the FDA-approval of 5 Companion Diagnostic (CDx) molecular assays, creating the global go-to-market strategy for a dozen of CDx at various stages in regulatory approval. Maude has educated pathologists and oncologists in early adoption of technologies that have changed medicine and cancer treatments in the last decade.

      Abstract

      NTRK fusions are rare but important recent biomarkers linked to response to new TRK inhibitors. Comprehensive genomic profiling on all solid tumors permits detection of rare genomic events and in the future may enables the use of emerging treatments such as NTRK inhibitors. NTRK genes include numerous potential fusion partners, large intronic regions and G-C rich content, making accurate and comprehensive detection of NTRK fusions difficult to perform in the lab. Amongst the variable performance of NTRK fusion assays, NTRK detection from RNA using Hybrid-Capture NGS provides comprehensive and accurate fusion detection, agnostic of the fusion partner. TruSightTM Oncology 500 is the latest comprehensive genomic profiling assay from Illumina and enables optimal NTRK fusion detection. 

      Learning Objectives:

      1. Value to adopt comprehensive genomic profiling in today's oncology care.
      2. How the Illumina TruSightTM Oncology 500 comprehensive genomic profiling assay enables optimal NTRK fusion detection. 


      Show Resources
      You May Also Like
      APR 07, 2020 8:00 AM PDT
      C.E. CREDITS
      APR 07, 2020 8:00 AM PDT
      DATE: April 7, 2020 TIME: 8:00am PT, 11:00am ET This webinar sets out to establish why quality control is key to robust, reliable, reproducible science. We will look at best practice criteri...
      JAN 23, 2020 9:00 AM PST
      C.E. CREDITS
      JAN 23, 2020 9:00 AM PST
      DATE: January 23, 2020 TIME: 9:00am PST, 12:00pm EST...
      MAY 08, 2020 10:00 AM PDT
      C.E. CREDITS
      MAY 08, 2020 10:00 AM PDT
      DATE: May 8, 2020 TIME: 10:00am PT, 11:00am MT, 1:00pm ET The application of next generation sequencing to interrogate immune repertoires and methods in which these highly complex dataset...
      FEB 26, 2020 9:00 AM PST
      C.E. CREDITS
      FEB 26, 2020 9:00 AM PST
      DATE: February 26, 2020 TIME: 9:00am PST 3D cell culture and analysis and the study of organoids and spheroids are becoming more prevalent as a research method in publications as traditional...
      JUN 09, 2020 10:00 AM PDT
      Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
      C.E. CREDITS
      JUN 09, 2020 10:00 AM PDT
      Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
      DATE: June 9, 2020 TIME: 10:00am PT, 1:00pm ET The presentation will first discuss sepsis as a disease and then explain the importance of performing diagnostic tests in the clinical labora...
      JUN 23, 2020 10:00 AM PDT
      Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
      C.E. CREDITS
      JUN 23, 2020 10:00 AM PDT
      Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
      DATE: June 23, 2020 TIME: 10:00am PT Human mesenchymal stromal or stem cells (MSCs)-based immunomodulation treatment has been proposed as a suitable therapeutic approach for many diseases, s...
      Loading Comments...
      Show Resources
      Attendees
      • See more